DEBATE: EVAS (Endovascular Aneurysm Sealing)
With The Nellix Device Is A Game Changer For Endo AAA Repair

Matt Thompson
St Georges Vascular Institute, London, UK

Financial Disclosure Slide
- Consultancy fees, Speakers bureau, Research funding
  - Medtronic
  - Endologix

Endovascular Aneurysm Sealing (EVAS)
- Disruptive, revolutionary, technology
- Increases patient access to endovascular therapy
- Addresses complications of EVAR – improves outcomes
- Alters biological process of Endo AAA Repair?

Endovascular treatment of abdominal aortic aneurysm: a failed experiment

The world potential market for copying machines is 5000 at most.” – 1894, to the eventual founders of Xerox, saying the photocopier had no market large enough to justify production, 1959

Karthikesalingam et al EJVES 2013

EVAS – Expanding Patient Applicability

Karthikesalingam et al EJVES 2013
Cases Good for Nellix: Not So Good for EVAR

EVAS and Parallel Grafts

Nellix – Clinical Performance – Global Registry

Endoleaks – Global Registry

Life and Death
MT 2015
Stokmans et al. EJVES 2012
Verhoeven et al EJVES 2014

Life and Death

<table>
<thead>
<tr>
<th></th>
<th>EVAS</th>
<th>ENGAGE</th>
<th>GREAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASA Class III/IV</td>
<td>64%</td>
<td>52%</td>
<td>63%</td>
</tr>
<tr>
<td>Cardiac History</td>
<td>53%</td>
<td>53%</td>
<td>39%</td>
</tr>
<tr>
<td>All Cause Death</td>
<td>5.1%</td>
<td>7.4%</td>
<td>7.0%</td>
</tr>
<tr>
<td>AAA-related mortality</td>
<td>1.4%</td>
<td>1.5%</td>
<td>NR</td>
</tr>
<tr>
<td>Acute Cardiac Death</td>
<td>0.4%</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Myocardial Infarction</td>
<td>1.1%</td>
<td>1.8%</td>
<td></td>
</tr>
</tbody>
</table>

MT 2015

- Expand patient population
- CHEVAS
- Reduce Type 2
- Biological efficacy
- Durability – to come

VEITH Symposium
Connecting the Vascular Community